CRF Health Announces an Open ePRO Integration Interface
CRF Health
announced an open ePRO integration interface, which enables Sponsors and CROs to integrate their own eClinical systems with CRF Health’s ePRO platform, TrialMax, to provide data collected from patients in real time to all study stakeholders.
The TrialMax Synapse open interface integrates ePRO data collected with CRF Health’s TrialMax platform to other eClinical systems in real time using the CDISC ODM standard. The current studies integrated to a EDC system are seeing a variety of benefits, including the enabling of sites to view all study data in one system, increasing the efficiency of drug accountability, facilitating data management, and allowing easier correlation of adverse events.
Rachael King, CEO of CRF Health, comments, “We have seen a significant increase in interest for integrating ePRO data to other eClinical systems, and are currently using integration in several studies. As the use of integration has exceeded all of our expectations, we decided to offer the possibility to all Sponsors and CROs that we are working with.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
